

<p>IN THIS ISSUE:</p> <ul style="list-style-type: none"> ▪ Increased Mumps Activity in Ontario ▪ NEW! Enhanced Pneumococcal Vaccine for Children up to 24 months of age 	<p>FROM: David L. Mowat, MBChB MPH FRCPC Medical Officer of Health</p>
--	---

Increased Mumps Activity in Ontario

Since September, 2009, 32 confirmed cases of mumps have been reported in Ontario. The cases range from 6 to 61 years of age, with a median age of 20.5 years. The majority of cases are male and aged 15 to 24.

Clinical Presentation of Mumps

- Acute onset of unilateral or bilateral **tender swelling of the parotid or other salivary gland** lasting two or more days without another apparent cause.
- **Orchitis**, usually unilateral (20%-30% of male cases)
- Non specific upper **respiratory symptoms** (40%-50%)

Diagnostic Testing for Suspect Cases

If possible, specimens for both virus isolation and serologic testing should be obtained early in the course of illness to confirm mumps infection.

1) Virus isolation:

Obtain up to 9 days after symptom onset:

- Buccal swab and / or
- Urine sample - clean catch

2) Serology

Acute Serology:

Obtain 3 to 5 days after symptom onset:

- A blood test for mumps IgM and IgG
- Detection of IgM confirms the diagnosis of mumps.

Convalescent serology:

Obtain a second test 14 days or more after symptom onset.

- Seroconversion or a four fold rise in IgG is indicative of recent infection.

Note: If the acute serology results show low, indeterminate or negative IgM and IgG, in a patient with symptoms and known or suspected exposure to mumps, both tests should be repeated in one to two weeks.

For timely processing, the laboratory requisition should:

- Include the reason for testing (e.g. mumps diagnosis)
- Include relevant clinical information (e.g. suspect mumps, recent vaccination history, date of onset of symptoms, or recent travel);
- Be marked "STAT"; and
- Be forwarded to Central Public Health Laboratory.

Immunization

The National Advisory Committee on Immunization (NACI) recommends that, secondary and postsecondary students should be offered a second dose of MMR vaccine if they have not already had two doses.

Mumps is a reportable disease. If you suspect a case of mumps, please contact Peel Public Health at 905-799-7700.

NEW! Enhanced Pneumococcal Vaccine for Children up to 24 months of age

In October 2009, a new **10-valent pneumococcal conjugate vaccine** (Synflorix™, GlaxoSmithKline) replaced the previous 7-valent pneumococcal vaccine (Prevnar®, Wyeth) for the immunization of children up to 24 months of age.

cont'd...

Background

- Synflorix contains 3 additional serogroups; 1, 5, and 7F.(in addition to 4, 6B, 9V, 14, 18C, 19F, and 23F.contained in Pevnar)
- Invasive Pneumococcal Disease (IPD: sepsis, bacteraemia, pneumonia and meningitis) rates have decreased in children since the introduction of Pevnar, however, there is a concern that serotype replacement is occurring.
- Cases of IPD due to serotype 5 have occurred in Ontario and there have been recent outbreaks of serotype 5 in Western Canada.

Vaccine Information

- Synflorix is licensed for use in Canada for children from 6 weeks to 24 months of age.
- The vaccine was tested in 4595 children during clinical trials. The most common adverse reactions were redness at the injection site and irritability which occurred after 38.3% and 52.3% of all doses respectively. 0.1% of children experienced serious adverse events associated with the vaccine.
- The vaccine is free for residents of Ontario and has replaced Pevnar in the routine schedule.
- Children who have started the series with Pevnar® should complete the series with the same vaccine.

Routine Immunization

- Synflorix™ should be administered at 2, 4, 6 and 15 months of age.
- Healthy children 12-23 months of age who missed their primary series should be offered two doses of Synflorix™.

High Risk Immunization

- Children 24 to 59 months of age who meet the MOHLTC high-risk eligibility criteria¹ should continue to receive two doses of Pevnar® two months apart.

¹<http://www.health.gov.on.ca/english/providers/program/immun/pdf/schedule.pdf>

Pneumococcal Vaccine Fact Sheet

http://www.health.gov.on.ca/english/public/pub/immun/pnem_conjugate.html

Product Monograph:

http://www.gsk.ca/english/docs-pdf/Synflorix_PM_20090505_EN.pdf